Integrative analysis of a novel 5 methylated snoRNA genes prognostic signature in patients with glioma

Abstract

Aim: To explore the prognostic value of methylated snoRNA genes in glioma and construct a prognostic risk signature. Materials & methods: We retrieved clinical information and 450K methylation data from The Cancer Genome Atlas and obtained five methylated snoRNA genes. Then we established a risk signature and verified the effect of SNORA71B on glioma cells with functional assays. Results: A risk signature containing five methylated snoRNA genes was constructed and demonstrated to be an independent predictor of glioma prognosis. Silencing SNORA71B restrained the proliferation, migration and invasion of glioma cells and reduced the expression of mesenchymal and cell cycle marker proteins. Conclusion: This study constructed a methylated snoRNA gene risk signature, which may provide a reference for glioma patients’ prognosis assessment.

Keywords::

• epigenetics
• glioma
• methylation
• prognosis
• risk signature
• snoRNA

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.tandfonline.com/doi/suppl/10.2217/epi-2022-0272

Author contributions

B Zhao and E Bian designed this article. X Yue and Y Zheng were responsible for data analysis and conducting practical experience. L Li was responsible for recording the experimental results. Z Yang and Z Chen were responsible for article figures. Y Wang, Z Wang and D Zhang drafted the article. All authors contributed to the article and approved the submitted version.

Acknowledgments

The authors thank TCGA network for its contributions.

Financial & competing interests disclosure

This research was supported by the National Natural Science Foundation of China (no. 81972348), Key Research and Development Plan Project of Anhui Province (no.1804h08020270), College Excellent Youth Talent Support Program in Anhui Province (no. gxypZD2019019), Key Projects of Natural Science Research in Anhui Province (KJ2019A0267), Academic Funding Project for Top Talents in Colleges and Universities in Anhui Province (no. gxbjZD10) and Nova Pew Plan of the Second Affiliated Hospital of Anhui Medical University (no. 2017KA01), Open Projects of Key Laboratory in Medical Physics and Technology of Anhui Province (LHJJ202001). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

All patients consented to an institutional review board-approved protocol that allows comprehensive analysis of tumor samples (Ethics Committee of the Second Affiliated Hospital of Anhui Medical University; protocol code: S20210098 and date of approval: December 2020). This study conforms to the Declaration of Helsinki.

Data availability statement

All data supporting this study are available upon request by contacting the corresponding authors.

Additional information

Funding

This research was supported by the National Natural Science Foundation of China (no. 81972348), Key Research and Development Plan Project of Anhui Province (no.1804h08020270), College Excellent Youth Talent Support Program in Anhui Province (no. gxypZD2019019), Key Projects of Natural Science Research in Anhui Province (KJ2019A0267), Academic Funding Project for Top Talents in Colleges and Universities in Anhui Province (no. gxbjZD10) and Nova Pew Plan of the Second Affiliated Hospital of Anhui Medical University (no. 2017KA01), Open Projects of Key Laboratory in Medical Physics and Technology of Anhui Province (LHJJ202001). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.